| Name | Title | Contact Details |
|---|
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).
EUSA Pharma Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioDuro, now a PPD company, is a leading integrated drug discovery outsourcing company that provides high-quality, integrated research and development services to meet the growing needs of the global biotechnology and pharmaceutical industries. Together, PPD and BioDuro have the expertise to perform a broad range of research and development services for pharmaceutical and biotech clients from discovery through Phase IV. Founded in 2005, BioDuro has more than 675 employees, the majority of whom are based in Beijing, where the company operates a state-of-the-art, 110,000-square-foot laboratory. BioDuro provides high-quality medicinal chemistry, discovery biology, pharmacology, synthesis, bioanalytical and drug safety evaluation services. Its discovery biology services range from reagent generation to assay development to screening and biochemistry.
Targacept`s clinical pipeline is built on a unique class of therapeutic targets.
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).